Search Tufts Medicine

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in patients with traumatic injury and confirmed or suspected acute major bleeding predicted to receive a large volume blood product transfusion. Randomization will be in a 1:1 ratio (BE1116:placebo) and stratified by study site. Subjects will receive a single IV infusion of either BE1116 or placebo, in addition to the study site's standard resuscitation methods and protocol.

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade E, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

The total duration of this study for each participant is approximately 165 weeks, which includes a screening period of 5 weeks, followed by a 16-week placebo-controlled period which will run concurrently with a 24-week active comparator-controlled period, followed by treatment with JNJ-77242113 200 mg once daily through Week 156 and a 4-week safety follow-up period.

Study DSP-5336-101 is a Phase 1/2, open-label, dose-escalation, dose-expansion study in which the safety, PK, pharmacodynamics, and clinical activity of orally administered DSP-5336 will be evaluated in adult patients with relapsed or refractory AML, ALL, or acute leukemia of ambiguous lineage, as well as in adult patients with high-risk relapsed or refractory MDS or relapsed/refractory MM.

12-Week open label clinical trial looking at the effects of nicotinamide riboside on bioenergetic metabolism, oxidative stress, and cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.

Observational study to evaluate new imaging methods and software of the Topcon prototype OCT instrument for ocular blood flow imaging of patients with different retinal diseases and healthy volunteers.

This is a single center prospective cohort study. The cohort (interventional) patients will receive the study intervention (ABCLO). The control group retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.

Breast cancer (BC) is the leading cause of cancer and the second most common cause of cancer related mortality in the United States. Although the prognosis of patients with BC has greatly improved over the past few years, there are still many unanswered questions. There is growing interest in identifying markers for treatment de-escalation or intensification in early and advanced breast cancer as well as in ductal carcinoma in situ (DCIS). Additionally, there are well known differences in disease biology and outcomes in groups from diverse genetic ancestry.

This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.

This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) [globally] or HER2-low [North America only] in routine clinical practice.

Patients receiving commercial CAR-T therapy for their clinical care are invited to provide 5 blood draws at the time blood is drawn for their clinical care. The samples will be used to help develop a new technology for detecting CAR-T cells in the blood.

This study seeks to obtain cancer and healthy tissue from women with metastatic ovarian cancer. The tissue will be used in a preclinical study to develop a multi-scale imaging probe that can better detect cancer metastases.

This research study will investigate the independent effects of an environmental intervention (E only), an individual-level eHealth phone program intervention (I only), or both (E+I) on changes in moderate intensity physical activity. A cluster randomized design will be implemented whereby all residents of one of 12 of Boston's public housing developments (PHDs) will be randomized to one of the four study groups (E only, I only, E+I, or control). The findings will inform future health promotion efforts among residents in public housing developments

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma, who have achieved a partial response or complete response after completing at least 12 weeks of platinum-based therapy.

This study will evaluate the safety and effectiveness outcomes of FRED X device in a population of patients that aligns with the indications for use of the FRED device. The data generated from this study will be compared to the safety and effectiveness of the FRED device by meeting the same performance goals established for the FRED pivotal study.